Cardiovascular Revascularization Medicine最新文献

{"title":"Finding the balance: Advancing strategies for managing severely calcified coronary lesions","authors":"Ricardo Fonseca Oliveira Suruagy Motta ,&nbsp;Anderson Matheus Pereira da Silva","doi":"10.1016/j.carrev.2025.01.004","DOIUrl":"10.1016/j.carrev.2025.01.004","url":null,"abstract":"<div><div>This letter to the editor provides a critical and constructive analysis of the article “<em>Intravascular Lithotripsy Compared with Rotational Atherectomy for Calcified Coronary Lesions: A Meta-analysis of Outcomes</em>”, highlighting key methodological limitations and the exclusion of relevant contemporary studies. It emphasizes the clinical importance of addressing severely calcified coronary lesions, a significant challenge in interventional cardiology, and advocates for future research to prioritize randomized clinical trials, subgroup analyses, and cost-effectiveness evaluations to improve the applicability of findings across healthcare settings. By promoting dialogue within the scientific community and encouraging the integration of evolving data, the letter aims to refine clinical strategies and align them with evidence-based public health approaches, particularly in resource-limited environments.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"75 ","pages":"Pages 147-148"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo biocompatibility of a new hydrophobic coated Al/Al2O3 nanowire surface on stents","authors":"Axel Rentzsch ,&nbsp;Eva Metz ,&nbsp;Ruben Mühl-Benninghaus ,&nbsp;Alexander Maßmann ,&nbsp;Stephanie Bettink ,&nbsp;Bruno Scheller ,&nbsp;Lilia Lemke ,&nbsp;Ali Awadelkareem ,&nbsp;Toshiki Tomori ,&nbsp;Ayman Haidar ,&nbsp;Matthias W. Laschke ,&nbsp;Michael D. Menger ,&nbsp;Cenk Aktas ,&nbsp;Matthias Hannig ,&nbsp;Norbert Pütz ,&nbsp;Thomas Büttner ,&nbsp;David Scheschkewitz ,&nbsp;Michael Veith ,&nbsp;Hashim Abdul-Khaliq","doi":"10.1016/j.carrev.2024.08.017","DOIUrl":"10.1016/j.carrev.2024.08.017","url":null,"abstract":"<div><h3>Background</h3><div>Intima proliferation and in-stent restenosis is a challenging situation in interventional treatment of small vessel obstruction. Al/Al₂O₃ nanowires have been shown to accelerate vascular endothelial cell proliferation and migration in vitro, while suppressing vascular smooth muscle cell growth. Moreover, surface modification of Al/Al₂O₃ nanowires with poly[bis(2,2,2-trifluoromethoxy)phosphazene (PTFEP) coating enables further advantages such as reduced platelet adhesion. Therefore, the study's goal was to compare the biocompatibility of novel Al/Al₂O₃ + PTFEP coated nanowire bare-metal stents to uncoated control stents in vivo using optical coherence tomography (OCT), quantitative angiography and histomorphometric assessment.</div></div><div><h3>Methods</h3><div>15 Al/Al₂O₃ + PTFEP coated and 19 control stents were implanted in the cervical arteries of 9 Aachen minipigs. After 90 days, in-stent stenosis, thrombogenicity, and inflammatory response were assessed. Scanning electron microscopy was used to analyse the stent surface.</div></div><div><h3>Results</h3><div>OCT analysis revealed that neointimal proliferation in Al/Al₂O₃ + PTFEP coated stents was significantly reduced compared to control stents. The neointimal area was 1.16 ± 0.77 mm² in Al/Al₂O₃ + PTFEP coated stents vs. 1.98 ± 1.04 mm² in control stents (<em>p</em> = 0.004), and the neointimal thickness was 0.28 ± 0.20 vs. 0.47 ± 0.10 (<em>p</em> = 0.003). Quantitative angiography showed a tendency to less neointimal growth in coated stents. Histomorphometry showed no significant difference between the two groups and revealed an apparent inflammatory reaction surrounding the stent struts.</div></div><div><h3>Conclusions</h3><div>At long-term follow-up, Al/Al₂O₃ + PTFEP coated stents placed in peripheral arteries demonstrated good tolerance with no treatment-associated vascular obstruction and reduced in-stent restenosis in OCT. These preliminary in vivo findings indicate that Al/Al₂O₃ + PTFEP coated nanowire stents may have translational potential to be used for the prevention of in-stent restenosis.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"75 ","pages":"Pages 31-38"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of high-risk characteristics of non-culprit plaques in relation to plaque severity in acute coronary syndrome","authors":"Mohamed M. Reda Abdelaziz Morsy ,&nbsp;Frans B. Mensink ,&nbsp;Jonathan Los ,&nbsp;Peter Damman ,&nbsp;Niels van Royen ,&nbsp;Mohamed A.H. Abdelhafez ,&nbsp;Hamdy Shams Eddin Mohamed ,&nbsp;Salwa R. Demitry ,&nbsp;Tim J.F. ten Cate ,&nbsp;Robert-Jan van Geuns","doi":"10.1016/j.carrev.2024.09.006","DOIUrl":"10.1016/j.carrev.2024.09.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with acute coronary syndrome (ACS) have high event rates related to non-culprit (NC) lesions, therefore plaque composition of these lesions is of great interest. Although marginal atherosclerotic lesions were studied extensively, more significant lesions might have more high-risk characteristics.</div></div><div><h3>Aim</h3><div>To compare differences in high-risk lesion characteristics between significant versus non-stenotic NC plaques in ACS and the discrepancies with chronic coronary syndrome (CCS) patients.</div></div><div><h3>Methods</h3><div>Non-culprit vessels of 26 ACS patients with 26 angiographically significant lesions and 37 patients (17 ACS and 20 CCS) with 48 non-stenotic lesions were investigated with intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Overall, 74 segments of 30 mm length were analyzed in 1 mm intervals. External elastic lamina (EEM), plaque burden (PB), minimal luminal area (MLA), percent atheroma volume (PAV) and lipid core burden index maximum 4 mm (maxLCBI_4mm) were determined for each segment.</div></div><div><h3>Results</h3><div>Cardiovascular risk factors were similar in all groups. PB was higher and MLA smaller in significant non-culprit ACS lesions vs non-stenotic lesions: PB 73.5% (IQR 68.7–78.5) vs 59.2 (IQR 49.6–71.5), <em>p</em> = 0.003, MLA 3.0 mm² (IQR 2.3–3.9) vs 4.0 mm² (IQR 2.8–4.7). MaxLCBI_4mm was similar 308.1 (±155.4) vs 287.8 (±165.7), <em>p</em> = 0.67.</div><div>Among non-stenotic plaques, MaxLCBI_4mm was comparable between ACS and CCS patients, 275.7 (±151.5) in CCS patients vs 287.8 (±165.7) in ACS patients, <em>p</em> = 0.79.</div></div><div><h3>Conclusion</h3><div>Although visually significant non-culprit lesions had a higher plaque burden compared to non-stenotic lesions, a significant relation between MaxLCBI_4mm and hemodynamic significance of the plaques couldn’t be established.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"75 ","pages":"Pages 80-83"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142336980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of invasive coronary angiography, management, and in-hospital outcomes among patients with non-ST-segment elevation myocardial infarction: A comprehensive nationwide analysis","authors":"Josip A. Borovac ,&nbsp;Konstantin Schwarz ,&nbsp;Adnan I. Qureshi ,&nbsp;Domenico D'Amario ,&nbsp;Dejan Milasinovic ,&nbsp;Maximillian Will ,&nbsp;Dino Miric ,&nbsp;Jaksa Zanchi ,&nbsp;Frane Runjic ,&nbsp;Anteo Bradaric ,&nbsp;Mislav Lozo ,&nbsp;Mihajlo Kovacic ,&nbsp;Mladen I. Vidovich ,&nbsp;Chun Shing Kwok","doi":"10.1016/j.carrev.2025.03.006","DOIUrl":"10.1016/j.carrev.2025.03.006","url":null,"abstract":"<div><h3>Background</h3><div>The impact of timing of invasive coronary angiography (ICA) and management strategies on in-hospital outcomes among unselected all-comers with non-ST-segment elevation myocardial infarction (NSTEMI) presents an equipoise in clinical practice.</div></div><div><h3>Methods</h3><div>Patients with NSTEMI from the US NIS database during 2016 to 2021 were included in the analysis. In-hospital outcomes were examined according to the timing of ICA - early (&lt;24 h), intermediate (24-72 h), and delayed (&gt;72 h). These outcomes included all-cause death, major adverse cardiovascular and cerebrovascular events (MACCE), major bleeding, reinfarctions, cardiovascular complications, and stroke.</div></div><div><h3>Results</h3><div>A total of 4,238,570 admissions with NSTEMI were screened of which 1,811,545 (42.7 %) received ICA. Most of patients (48.9 %) received ICA during 2nd and 3rd day following admission, whereas 32.5 % and 18.6 % received early and delayed ICA, respectively. Percutaneous coronary intervention (PCI) was performed in 54.7 %, 47.8 %, and 37.1 % of cases among patients that underwent ICA &lt;24 h, 24-72 h, and &gt; 72 h, respectively. Patients receiving delayed ICA were more likely to be older, women, have more comorbidites and high-risk features. Compared to ICA &lt;24 h, ICA performed at 24–72 h was associated with reduced odds of death (OR 0.80), MACCE (OR 0.85), reinfarction (OR 0.63), and cardiovascular complications (OR 0.89) with no difference concerning major bleeding and stroke.</div></div><div><h3>Conclusions</h3><div>&lt;50 % of patients with NSTEMI in a contemporary nationwide US cohort receive ICA while 1 in 2 patients out of those receive PCI. ICA timing at 24–72 h appears to provide the optimal safety profile with respect to primary outcomes and complications.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"75 ","pages":"Pages 98-104"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Are polymer-coated non-drug-eluting stents threatening the kingdom of drug-eluting stents?","authors":"Fernando Alfonso ,&nbsp;Lidia Vilches,&nbsp;Fernando Rivero","doi":"10.1016/j.carrev.2025.03.016","DOIUrl":"10.1016/j.carrev.2025.03.016","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"75 ","pages":"Pages 23-24"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete versus incomplete revascularization in patients with a non-ST-elevation myocardial infarction: Analysis from the e-ULTIMASTER registry","authors":"Victor A. Jiménez Díaz ,&nbsp;Helen Routledge ,&nbsp;Fazila-Tun-Nesa Malik ,&nbsp;David Hildick-Smith ,&nbsp;Antoine Guédès ,&nbsp;Pascual Baello ,&nbsp;Shoichi Kuramitsu ,&nbsp;Rajiv Das ,&nbsp;Willem Dewilde ,&nbsp;Javier Fernandez Portales ,&nbsp;Michael Angioi ,&nbsp;Pieter C. Smits ,&nbsp;Andrés Iñiguez Romo","doi":"10.1016/j.carrev.2024.07.011","DOIUrl":"10.1016/j.carrev.2024.07.011","url":null,"abstract":"<div><h3>Background</h3><div>Incomplete revascularization (ICR) has been associated with a worse prognosis after a percutaneous coronary intervention (PCI). In NSTEMI patients with multivessel disease (MVD) however, the benefit of a complete revascularization (CR) remains unclear.</div></div><div><h3>Methods</h3><div>Patients presenting with an NSTEMI and MVD were selected from the global e-ULTIMASTER registry and grouped according to completeness of revascularization at index hospitalization discharge. The primary endpoint was the patient oriented composite endpoint (POCE) defined as all death, any myocardial infarction, and any revascularization at 1 year. Target lesion failure (TLF) was defined as the composite of cardiac death, target vessel related myocardial infarction and clinically driven target lesion revascularization. Inverse propensity score weighting (IPSW) was performed to harmonize the patient's baseline characteristics between the groups.</div></div><div><h3>Results</h3><div>CR was achieved in 1800 patients (47.0 %) and ICR in 2032 patients (53.0 %). The incidence of POCE at 1 year was lower in the CR group compared to the ICR group: 7.0 % vs. 12.9 %, <em>p</em> &lt; 0.0001. Similarly for TLF at 1 year: 3.6 % vs. 5.5 %, <em>p</em> &lt; 0.01. After IPSW, the incidence of POCE was 7.7 % vs. 12.0 %, p &lt; 0.0001, due to a lower all-cause mortality: 2.7 % vs. 4.2 %, <em>p</em> = 0.02 and less revascularizations: 4.9 % vs. 7.9 %, <em>p</em> &lt; 0.001. The incidence of TLF was no longer statistically significant: CR 3.9 % vs. IR 5.0 %, <em>p</em> = 0.10.</div></div><div><h3>Conclusions</h3><div>Patients with a NSTEMI and multi vessel disease undergoing a percutaneous coronary revascularization with a complete revascularization during index hospitalization have better 1-year clinical outcomes. Randomized studies are warranted to confirm these results.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"75 ","pages":"Pages 25-30"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141853763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of the unilateral, suture-based, dry-closure technique in percutaneous trans-axillary aortic valve implantation","authors":"Rutger-Jan Nuis ,&nbsp;Thijmen W. Hokken ,&nbsp;Jenna van Niekerk ,&nbsp;Lucas Uchoa de Assis ,&nbsp;Rik Adrichem ,&nbsp;Mark van den Dorpel ,&nbsp;Joris Ooms ,&nbsp;Isabella Kardys ,&nbsp;Mattie Lenzen ,&nbsp;Joost Daemen ,&nbsp;Nicolas M. Van Mieghem","doi":"10.1016/j.carrev.2025.02.006","DOIUrl":"10.1016/j.carrev.2025.02.006","url":null,"abstract":"<div><h3>Background</h3><div>Transaxillary transcatheter aortic valve implantation (TAx-TAVI) is the most used alternative access when severe iliofemoral disease renders transfemoral access infeasible. Compared to surgical transaxillary access, a true percutaneous approach using vascular closure devices (VCD) has advantages but can be challenging. Herein, we describe the impact of the <em>“unilateral, suture-mediated, dry-closure technique”</em> on vascular safety and efficacy in patients undergoing true percutaneous TAx-TAVI.</div></div><div><h3>Methods</h3><div>A total of 77 patients undergoing percutaneous TAx-TAVI were categorized into a cohort before (C1, <em>n</em> = 40) and after (C2, <em>n</em> = 37) implementation of the suture-based dry-closure technique using an upstream occlusion balloon. In C1, arteriotomy closure mainly consisted of plug-based VCD. The primary (safety) endpoint was occurrence of major or minor access-site related vascular complications in accordance with Valve Academic Research Consortium 3 criteria. Technical success rates (at exit from procedure room) were used to assess procedural efficacy.</div></div><div><h3>Results</h3><div>The mean age of the study population was 79 ± 7 years and 49 % were male. From C1 to C2, the Society of Thoracic Surgeons Predicted Risk of Mortality reduced numerically (from 4.1 to 3.6 %, <em>p</em> = 0.060). Procedures became more streamlined with use of local anesthesia in 100 % (83 % in C2) and the left axillary artery in 76 % (68 % in C2). The primary (safety) endpoint occurred in 34 % of the patients, but reduced from 45 % in C1 to 16 % in C2 (<em>p</em> = 0.011). Concurrently, there was a reduction in VCD failure (45 vs 14 % [incomplete arteriotomy closure in all 5 cases], <em>p</em> = 0.003), bleeding complications (45 vs 14 %, p = 0.003) and bailout vascular surgery/stenting (40 % vs. 16 %, <em>p</em> = 0.021). Technical success was 80 % in C1 and 87 % in C2 (<em>p</em> = 0.45) and median length of hospital stay reduced from 5 (25th–75th percentile: 2–7) to 3 days (25th–75th percentile: 2–5, <em>p</em> = 0.080).</div></div><div><h3>Conclusions</h3><div>The unilateral, suture-based dry-closure technique facilitates safe and effective access management in high-risk patients selected for percutaneous TAx-TAVI procedures.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"75 ","pages":"Pages 46-51"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term follow up of patients treated with a polymer coated non drug-eluting stent in the COBRA-REDUCE trial","authors":"Jola Bresha ,&nbsp;Karsten P. Hug ,&nbsp;Robert A. Byrne ,&nbsp;Shqipdona Lahu ,&nbsp;Salvatore Cassese ,&nbsp;Roisin Colleran ,&nbsp;Tareq Ibrahim ,&nbsp;Erion Xhepa ,&nbsp;Isabell Bernlochner ,&nbsp;Michael Joner ,&nbsp;Karl-Ludwig Laugwitz ,&nbsp;Adnan Kastrati ,&nbsp;Sebastian Kufner ,&nbsp;J.J. Coughlan ,&nbsp;COBRA-REDUCE investigators","doi":"10.1016/j.carrev.2025.02.014","DOIUrl":"10.1016/j.carrev.2025.02.014","url":null,"abstract":"<div><h3>Background</h3><div>The use of a non-drug eluting coronary stent with a thromboresistant and pro-healing coating may result in long term advantages in comparison to FDA approved drug eluting stents (DES).</div></div><div><h3>Methods</h3><div>In the COBRA REDUCE trial, patients with an indication for OAC undergoing PCI were randomized to treatment with the COBRA-PzF stent followed by 14 days of DAPT or an FDA-approved new generation DES followed by 3- or 6-months of DAPT. In the subset of patients enrolled at the lead site, we collected additional long term follow up. The primary endpoints for the current analysis were a composite thromboembolic endpoint (all-cause death, myocardial infarction, definite or probable stent thrombosis, or ischaemic stroke) and ischemia driven target lesion revascularisation (ID-TLR) through to 4 years follow up.</div></div><div><h3>Results</h3><div>A total of 996 patients underwent randomization in the COBRA REDUCE trial. Of 140 patients randomized in Munich, 71 were randomized to the COBRA PzF stent and 69 to the control group. The primary composite ischemic endpoint occurred in 15/71 patients (21.8 %) in the COBRA PzF group and 15/69 patients (22.4 %) in the control group (hazard ratio [HR], 0.96; 95 % confidence interval [CI], 0.47–1.97, <em>p</em> value = 0.92). ID-TLR occurred in 7/71 patients (10.1 %) in the COBRA PzF group and 3/69 patients (4.5 %) in the control group (HR, 2.30; 95 % CI, 0.60–8.77, <em>p</em> value = 0.22). TLR occurred in 11/71 patients (15.8 %) in the COBRA PzF group and 3/69 patients (4.5 %) in the control group (HR, 3.76; 95 % CI, 1.06 to 13.32, p value = 0.04).</div></div><div><h3>Conclusion</h3><div>Through to 4 year follow up after PCI in patients with an indication for OAC, the COBRA PzF stent did not result in any advantages in comparison to FDA approved DES and was associated with an increased risk of TLR.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"75 ","pages":"Pages 15-22"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Transaxillary large bore access: A method to stay dry and steer clear of the storm","authors":"Itsik Ben-Dor","doi":"10.1016/j.carrev.2025.04.009","DOIUrl":"10.1016/j.carrev.2025.04.009","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"75 ","pages":"Pages 52-55"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary bifurcation lesion treatment with the BioMime™ Branch sirolimus-eluting coronary side-branch stent system: A single-center experience","authors":"Antonio L. Bartorelli ,&nbsp;Giovanni Monizzi ,&nbsp;Luca Grancini ,&nbsp;Emanuele Gallinoro ,&nbsp;Angelo Mastrangelo ,&nbsp;Vincenzo Mallia ,&nbsp;Franco Fabbiocchi","doi":"10.1016/j.carrev.2024.08.018","DOIUrl":"10.1016/j.carrev.2024.08.018","url":null,"abstract":"<div><h3>Background</h3><div>Coronary bifurcation lesions (CBL) comprise 15 %–20 % of percutaneous coronary procedures and remain a challenge despite advances in stent and interventional techniques. The BioMime™ Branch sirolimus-eluting coronary side-branch stent (BBSES) is specifically designed for CBL treatment in conjunction with a standard drug-eluting stent (DES). We report the first single-center experience of treating complex CBL with the novel BBSES.</div></div><div><h3>Methods</h3><div>This is a retrospective, single-center study involving consecutive prospectively identified patients who underwent treatment of true CBL with the BBSES. The protocol included BBSES+DES implantation in the CBL and simultaneous final kissing balloon inflation.</div></div><div><h3>Results</h3><div>Fifty-eight CBL were treated in 58 consecutive patients (89.6 % men, mean age 69.0 ± 9.5 years) presenting primarily with stable angina (84.4 %) and true (Medina 1,1,1,) CBL. Procedural success was 100 % without major adverse cardiac events (MACE). At a median follow-up of 18 months, one sudden death was reported that was accounted as possible late stent thrombosis. One patient had spontaneous myocardial infarction due to subacute thrombosis of a DES implanted in the main vessel proximally to the BBSES before the index procedure. Another patient was hospitalized for atrial fibrillation.</div></div><div><h3>Conclusions</h3><div>This is the first clinical experience to date of true CBL treatment with the BBSES demonstrating high procedural success, no in-hospital MACE and sustained clinical results at a median follow-up of 18 months.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"75 ","pages":"Pages 39-45"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}